explore -WSS

explore

author：entertainment 2025-09-28 22:53:42 - browse：2

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Report: NIH

explore

WSS

Health insurers say they are turning to AI to cut costs, improve care

Security flaws in third

A letter from the executive editor: The 2023 STATUS List

iTeos Therapeutics debuts first data on TIGIT

Prosthetic arm enables patients to feel the objects they grip

Vertex cell therapy lets patients with type 1 diabetes stop insulin

hotspot

explore

Lobbying power of AI, software-enabled devices

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

iTeos Therapeutics debuts first data on TIGIT

Affirmative action in medical school literally saved lives

Undocumented workers face uncertainty as immigration law takes effect in Florida

Medical records are filled with copy

First Opinion Podcast: What happens when kids become caregivers?

What does generative AI mean for health care? We asked experts

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Virginia high school admissions case could be legal follow

UpToDate has a racism problem: Dr. Stanley Goldfarb

explore

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Addiction doctors spar with methadone clinics over legislation

Undocumented workers face uncertainty as immigration law takes effect in Florida

Report: NIH

Adam's Biotech Scorecard: Do Sarepta's exon

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

explore

explore

hotspot

Wikipedia